Document Detail


Multiple Mechanisms of Ligand Interaction with the Human Organic Cation Transporter, OCT2.
MedLine Citation:
PMID:  23034939     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
OCT2 is the entry step for organic cation (OC) secretion by renal proximal tubules. Although many drugs inhibit OCT2 activity, neither the mechanistic basis of their inhibition nor their transport status is generally known. Using representatives of several structural classes of OCT2 inhibitory ligands recently described by Kido et al. (24), we determined the kinetic basis of their inhibition of 1-methyl-4-phenylpyridinium (MPP) transport into CHO cells that stably expressed hOCT2. The 'Cluster II' inhibitors (which contains known OCT2 substrates), metformin and cimetidine, interacted competitively with MPP. However, other Cluster II compounds, including tetraethylammonium (TEA), diphenidol and phenyltoloxamine, were mixed-type inhibitors of MPP transport (i.e., decreasing J(max) and increasing K(t)). A Cluster III (neutral steroid) representative, adrenosterone, and a Cluster I (large, flexible cation) representative, carvedilol, displayed noncompetitive inhibitory profiles. Competitive Counterflow (CCF) was used to determine if the inhibitory ligands served as substrates of hOCT2. Carvedilol (Cluster I) and adrenosterone (Cluster III) did not support CCF, consistent with the prediction that members of these structural classes are likely to be nontransported inhibitors of OCT2. The Cluster II representatives MPP, metformin, cimetidine and TEA all supported CED, consistent with independent assessments of their OCT2-mediated transport. However, the other Cluster II representatives, diphenidol and phenyltoloxamine, failed to support CCF, suggesting that neither compound is transported by OCT2. An independent assessment of diphenidol transport (using liquid chromatography with tandem mass spectroscopy) confirmed this observation. The results underscore the caution required for development of predictive models of ligand interaction with multidrug transporters.
Authors:
Jaclyn N Harper; Stephen H Wright
Related Documents :
23291469 - Detection of a quaternary organization into dimer of trimers of corynebacterium ammonia...
23667909 - Mast cells limit extracellular levels of il-13 via a serglycin proteoglycan-serine prot...
2400399 - Effect of n-methylation on the modulation by synthetic peptides of the activity of the ...
22982109 - Inhibition of a cold-active alkaline phosphatase by imipenem revealed by in silico mode...
17825449 - Directed evolution of transketolase activity on non-phosphorylated substrates.
23514429 - Tracing the interstitial carbide of the nitrogenase cofactor during substrate turnover.
7988699 - A point mutation within the atp-binding site inactivates both catalytic functions of th...
19325759 - Effect of locked-nucleic acid on a biologically active g-quadruplex. a structure-activi...
21311779 - Protein-inspired modified dnazymes: dramatic effects of shortening side-chain length of...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-10-3
Journal Detail:
Title:  American journal of physiology. Renal physiology     Volume:  -     ISSN:  1522-1466     ISO Abbreviation:  Am. J. Physiol. Renal Physiol.     Publication Date:  2012 Oct 
Date Detail:
Created Date:  2012-10-4     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100901990     Medline TA:  Am J Physiol Renal Physiol     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1University of Arizona.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Zona occludens-2 protects against podocyte dysfunction induced by ADR in mice.
Next Document:  A regulated NH2-terminal Sgk1 variant with enhanced function is expressed in the collecting duct.